Gilead Sciences
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell GILD and other ETFs, options, and stocks.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
GILD News
Loading... Loading... Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore....
Gilead Sciences, Inc. GILD reported better-than-expected results in the first quarter, as its loss was narrower than expected and sales beat estimates. GILD’s...
Participants Andrew D. Dickinson; CFO; Gilead Sciences, Inc. Cindy Perettie; EVP of Kite; Gilead Sciences, Inc. Daniel P. O'Day; Chairman & CEO; Gilead Scien...
Analyst ratings
56%
of 32 ratingsMore GILD News
Total Revenue: Reached $6.7 billion in Q1 2024, a 5% increase year-over-year, exceeding estimates of $6.338 billion. Net Loss: Reported a significant net loss...
Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1...
By Deena Beasley (Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver dr...
Gilead Sciences (GILD) beat Wall Street's first-quarter sales forecasts Thursday on the back of its Covid treatment, Veklury, but lighter-than-expected sales of...
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increas...
Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q1 earnings results on Thursday, April 25th, after market close. Analysts estimate a loss of $1.54 per s...
The first-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device c...
